
### [MONDO:0016599](http://purl.obolibrary.org/obo/MONDO_0016599)
**Label:** autosomal dominant secondary polycythemia

**Subclasses:** [MONDO:0012729](http://purl.obolibrary.org/obo/MONDO_0012729) (erythrocytosis, familial, 4), [MONDO:0012353](http://purl.obolibrary.org/obo/MONDO_0012353) (erythrocytosis, familial, 3), 

**Mapped go classes:** [GO:0016705](http://purl.obolibrary.org/obo/GO_0016705) (oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen), [GO:0016706](http://purl.obolibrary.org/obo/GO_0016706) (oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors), [GO:0000976](http://purl.obolibrary.org/obo/GO_0000976) (transcription regulatory region sequence-specific DNA binding), [GO:0045765](http://purl.obolibrary.org/obo/GO_0045765) (regulation of angiogenesis), [GO:0043565](http://purl.obolibrary.org/obo/GO_0043565) (sequence-specific DNA binding), [GO:0045944](http://purl.obolibrary.org/obo/GO_0045944) (positive regulation of transcription by RNA polymerase II), [GO:0043523](http://purl.obolibrary.org/obo/GO_0043523) (regulation of neuron apoptotic process), [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component), [GO:0060347](http://purl.obolibrary.org/obo/GO_0060347) (heart trabecula formation), [GO:0006879](http://purl.obolibrary.org/obo/GO_0006879) (cellular iron ion homeostasis), [GO:0005667](http://purl.obolibrary.org/obo/GO_0005667) (transcription factor complex), [GO:0030821](http://purl.obolibrary.org/obo/GO_0030821) (negative regulation of cAMP catabolic process), [GO:0031418](http://purl.obolibrary.org/obo/GO_0031418) (L-ascorbic acid binding), [GO:0003700](http://purl.obolibrary.org/obo/GO_0003700) (DNA binding transcription factor activity), [GO:0001666](http://purl.obolibrary.org/obo/GO_0001666) (response to hypoxia), [GO:0051344](http://purl.obolibrary.org/obo/GO_0051344) (negative regulation of cyclic-nucleotide phosphodiesterase activity), [GO:1990402](http://purl.obolibrary.org/obo/GO_1990402) (embryonic liver development), [GO:0048565](http://purl.obolibrary.org/obo/GO_0048565) (digestive tract development), [GO:0005506](http://purl.obolibrary.org/obo/GO_0005506) (iron ion binding), [GO:0016491](http://purl.obolibrary.org/obo/GO_0016491) (oxidoreductase activity), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0032364](http://purl.obolibrary.org/obo/GO_0032364) (oxygen homeostasis), [GO:0071731](http://purl.obolibrary.org/obo/GO_0071731) (response to nitric oxide), [GO:0031017](http://purl.obolibrary.org/obo/GO_0031017) (exocrine pancreas development), [GO:0051402](http://purl.obolibrary.org/obo/GO_0051402) (neuron apoptotic process), [GO:0055008](http://purl.obolibrary.org/obo/GO_0055008) (cardiac muscle tissue morphogenesis), [GO:0030182](http://purl.obolibrary.org/obo/GO_0030182) (neuron differentiation), [GO:0006351](http://purl.obolibrary.org/obo/GO_0006351) (transcription, DNA-templated), [GO:0006355](http://purl.obolibrary.org/obo/GO_0006355) (regulation of transcription, DNA-templated), [GO:0046983](http://purl.obolibrary.org/obo/GO_0046983) (protein dimerization activity), [GO:0043433](http://purl.obolibrary.org/obo/GO_0043433) (negative regulation of DNA binding transcription factor activity), [GO:1901214](http://purl.obolibrary.org/obo/GO_1901214) (regulation of neuron death), [GO:0060412](http://purl.obolibrary.org/obo/GO_0060412) (ventricular septum morphogenesis), [GO:1901216](http://purl.obolibrary.org/obo/GO_1901216) (positive regulation of neuron death), [GO:0000981](http://purl.obolibrary.org/obo/GO_0000981) (RNA polymerase II transcription factor activity, sequence-specific DNA binding), [GO:0060711](http://purl.obolibrary.org/obo/GO_0060711) (labyrinthine layer development), [GO:0051213](http://purl.obolibrary.org/obo/GO_0051213) (dioxygenase activity), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0046872](http://purl.obolibrary.org/obo/GO_0046872) (metal ion binding), [GO:0043065](http://purl.obolibrary.org/obo/GO_0043065) (positive regulation of apoptotic process), [GO:1905290](http://purl.obolibrary.org/obo/GO_1905290) (negative regulation of CAMKK-AMPK signaling cascade), [GO:0055114](http://purl.obolibrary.org/obo/GO_0055114) (oxidation-reduction process), [GO:0014823](http://purl.obolibrary.org/obo/GO_0014823) (response to activity), [GO:0031545](http://purl.obolibrary.org/obo/GO_0031545) (peptidyl-proline 4-dioxygenase activity), [GO:0018401](http://purl.obolibrary.org/obo/GO_0018401) (peptidyl-proline hydroxylation to 4-hydroxy-L-proline), [GO:0031543](http://purl.obolibrary.org/obo/GO_0031543) (peptidyl-proline dioxygenase activity), [GO:0019899](http://purl.obolibrary.org/obo/GO_0019899) (enzyme binding), 

**Class expressions from DL-Learner:**

- [GO:1990402](http://purl.obolibrary.org/obo/GO_1990402) (embryonic liver development) 55.00%
- [GO:0060711](http://purl.obolibrary.org/obo/GO_0060711) (labyrinthine layer development) 55.00%
- [GO:0060347](http://purl.obolibrary.org/obo/GO_0060347) (heart trabecula formation) 55.00%
- [GO:0051344](http://purl.obolibrary.org/obo/GO_0051344) (negative regulation of cyclic-nucleotide phosphodiesterase activity) 55.00%
- [GO:0032364](http://purl.obolibrary.org/obo/GO_0032364) (oxygen homeostasis) 55.00%
- [GO:0031017](http://purl.obolibrary.org/obo/GO_0031017) (exocrine pancreas development) 55.00%
- [GO:0018401](http://purl.obolibrary.org/obo/GO_0018401) (peptidyl-proline hydroxylation to 4-hydroxy-L-proline) 55.00%
- [GO:0051342](http://purl.obolibrary.org/obo/GO_0051342) (regulation of cyclic-nucleotide phosphodiesterase activity) and [GO:0051346](http://purl.obolibrary.org/obo/GO_0051346) (negative regulation of hydrolase activity) 55.00%
- [GO:0044092](http://purl.obolibrary.org/obo/GO_0044092) (negative regulation of molecular function) and [GO:0051342](http://purl.obolibrary.org/obo/GO_0051342) (regulation of cyclic-nucleotide phosphodiesterase activity) 55.00%
- [GO:0043086](http://purl.obolibrary.org/obo/GO_0043086) (negative regulation of catalytic activity) and [GO:0051342](http://purl.obolibrary.org/obo/GO_0051342) (regulation of cyclic-nucleotide phosphodiesterase activity) 55.00%
- [GO:0019471](http://purl.obolibrary.org/obo/GO_0019471) (4-hydroxyproline metabolic process) and [GO:0044267](http://purl.obolibrary.org/obo/GO_0044267) (cellular protein metabolic process) 55.00%
- [GO:0019471](http://purl.obolibrary.org/obo/GO_0019471) (4-hydroxyproline metabolic process) and [GO:0044260](http://purl.obolibrary.org/obo/GO_0044260) (cellular macromolecule metabolic process) 55.00%
- [GO:0019471](http://purl.obolibrary.org/obo/GO_0019471) (4-hydroxyproline metabolic process) and [GO:0043412](http://purl.obolibrary.org/obo/GO_0043412) (macromolecule modification) 55.00%
- [GO:0019471](http://purl.obolibrary.org/obo/GO_0019471) (4-hydroxyproline metabolic process) and [GO:0043170](http://purl.obolibrary.org/obo/GO_0043170) (macromolecule metabolic process) 55.00%
- [GO:0019471](http://purl.obolibrary.org/obo/GO_0019471) (4-hydroxyproline metabolic process) and [GO:0036211](http://purl.obolibrary.org/obo/GO_0036211) (protein modification process) 55.00%


